ProPhase Labs advances cancer treatment with AI

GARDEN CITY, NY - ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has unveiled Project ZenQ-AI, a new initiative aimed at enhancing cancer treatment research. The project utilizes the company's advanced artificial intelligence (AI) platform, alongside a comprehensive genomic database, to develop antibody drug conjugates (ADCs) for cancer therapeutics.

The company's AI platform, developed in collaboration with leading AI technology providers, leverages whole genome sequencing (WGS) data from over 130 countries, equivalent to approximately 150 million ancestry SNP-based tests. WGS captures all three billion base pairs of an individual's DNA, in contrast to SNP testing which targets specific genetic variations. This allows for a more precise approach in personalized medicine and genetic research.

Project ZenQ-AI integrates this genomic data with findings from ProPhase Labs' BE-Smart Test for esophageal adenocarcinoma (EAC), using algorithms to identify potential ADC candidates. ADCs are treatments that deliver chemotherapy agents directly to cancer cells, minimizing damage to healthy cells.

Ted Karkus, CEO at ProPhase Labs, emphasized the project's innovative combination of AI and genomic data, which enhances the company's approach to cancer treatment. The project also leverages on-premises NVIDIA (NASDAQ:NVDA) hardware and cloud-based AI and machine learning capabilities, as explained by Sergio Miralles, CIO at ProPhase.

The BE-Smart initiative, part of Project ZenQ-AI, has been in development for over six years and focuses on EAC, a cancer with a high mortality rate and limited treatment options. Initial testing by mProbe, Inc. on human samples has shown promising accuracy in early EAC detection. The company plans to commercialize the BE-Smart diagnostic test in the second half of 2024.

ProPhase Labs believes that the global diversity of its genomic database, including data from Nebula Genomics, will enhance the development of algorithms for identifying unique genetic markers and therapeutic targets, potentially leading to more effective ADC treatments.

The company's strategy includes out-licensing potential discoveries to major pharmaceutical companies, which could provide a cost-effective and low-risk model for shareholders. ProPhase Labs invites collaboration from the scientific and medical communities to join this transformative cancer treatment initiative.

This information is based on a press release statement from ProPhase Labs, Inc. The company is known for its innovative solutions in biopharma, genomics, diagnostics, and therapeutics, and is committed to advancing personalized medicine and improving patient care.

As ProPhase Labs, Inc. (NASDAQ: PRPH) embarks on its ambitious Project ZenQ-AI to revolutionize cancer treatment research, investors are closely monitoring the company's financial health and stock performance. Here are some key insights from InvestingPro:

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

InvestingPro Data shows a current Market Cap of 111.07M USD, indicating the size and scale of the company within the biotech sector. Despite the innovative strides in Project ZenQ-AI, ProPhase Labs has a negative P/E Ratio (Adjusted) as of Q4 2023 at -6.61, reflecting challenges in profitability. Moreover, the company has experienced a significant Revenue Growth decline of -63.81% over the last twelve months as of Q4 2023.

An InvestingPro Tip worth noting is that analysts anticipate a sales decline in the current year, which could impact the company's financial position and its ability to invest in research and development. Additionally, ProPhase Labs does not pay a dividend to shareholders, which might affect the investment decision for those seeking regular income.

For investors looking for more in-depth analysis and additional InvestingPro Tips, there are 13 more tips available on ProPhase Labs. These tips can provide a broader perspective on the company's stock performance and financial health. To access these tips and more, visit https://www.investing.com/pro/PRPH and remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.